ArticleJournal of molecular histology2026
Lasiokaurin suppresses hepatocellular carcinoma proliferation and induces apoptosis via the JAK2/STAT3 pathway.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The antitumor effects of Lasiokaurin (LAS), a natural compound derived from traditional Chinese medicine extracts, remain poorly understood in hepatocellular carcinoma (HCC). Therefore, this study investigates the anticancer effects of LAS in liver cancer. The experiment employed Wound healing assay, colony formation assays, Transwell assays, flow cytometry, Western blot analysis, and reverse transcription quantitative polymerase chain reaction (RT-qPCR) to evaluate the relationship between LAS and apoptosis, migration, proliferation, and cell cycle arrest. RNA-sequencing, RT-qPCR, and Western blot techniques were used to detect markers associated with the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway. The anti-tumor efficacy was assessed using a subcutaneous tumor-bearing mouse model. LAS promotes apoptosis and cell cycle arrest, significantly inhibiting tumor growth. These findings indicate that LAS mediates apoptosis through the JAK2/STAT3 pathway, suggesting its potential as a novel anticancer agent.
Indexed as
Identifiers
42399563What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.